Pfizer More Than Doubles Earnings, Sales In Q3; Forecasts $36B From COVID-19 Vax Sales In FY21

  • Pfizer Inc PFE reported Q3 adjusted EPS of $1.34, well ahead of the consensus of $1.09, and more than doubled from $0.59 posted a year ago. 
  • The Company achieved Q3 revenues of $24.09 billion, more than doubled, reflecting operational growth of $13.4 billion and the favorable impact of foreign exchange of $421 million, surpassing the Wall Street estimate of $22.71 billion.
  • Its COVID-19 vaccine, Comirnaty, contributed $13.0 billion in direct sales and alliance revenues.
  • Other products, including Eliquis, Vyndaqel/Vyndamax, Inlyta, Xtandi, and Ibrance, contributed to the strength.
  • Chantix sales declined 97%, driven by the voluntary recall, and Prevnar sales dipped 7% due to the ongoing prioritization of primary and booster vaccination campaigns for COVID-19.
  • FY21 Outlook: Pfizer raised FY21 revenue outlook 81 billion - $82.0 billion, up from prior guidance of $78 billion - $80 billion. It expects EPS of $4.13 - $4.18, higher than the previous outlook of $3.95-$4.05.
  • Pfizer has raised its revenue expectation from the COVID-19 vaccine by $2.5 billion to approximately $36 billion.
  • Price Action: PFE shares are up 3.12% at $45 during the premarket session on the last check Tuesday.
  • Photo by x3 from Pixabay
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLong IdeasNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!